168 related articles for article (PubMed ID: 8271061)
1. Iodine-123-Tyr-3-octreotide uptake in pancreatic endocrine tumors and in carcinoids in relation to hormonal inhibition by octreotide.
Nocaudie-Calzada M; Huglo D; Deveaux M; Carnaille B; Proye C; Marchandise X
J Nucl Med; 1994 Jan; 35(1):57-62. PubMed ID: 8271061
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin-receptor scintigraphy in the management of gastroenteropancreatic tumors.
Krausz Y; Bar-Ziv J; de Jong RB; Ish-Shalom S; Chisin R; Shibley N; Glaser B
Am J Gastroenterol; 1998 Jan; 93(1):66-70. PubMed ID: 9448177
[TBL] [Abstract][Full Text] [Related]
3. 111In-octreotide scintigraphy in endocrine tumors. Preliminary data.
Cremonini N; Furno A; Sforza A; Chiarini V; Graziano E; Zampa G; Turba E
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):116-20. PubMed ID: 9002767
[TBL] [Abstract][Full Text] [Related]
4. A scintigraphic comparison of iodine-123-metaiodobenzylguanidine and an iodine-labeled somatostatin analog (Tyr-3-octreotide) in metastatic carcinoid tumors.
Bomanji J; Mather S; Moyes J; Ellison D; Grossman A; Britton KE; Besser GM
J Nucl Med; 1992 Jun; 33(6):1121-4. PubMed ID: 1597726
[TBL] [Abstract][Full Text] [Related]
5. Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy.
Lamberts SW; Hofland LJ; van Koetsveld PM; Reubi JC; Bruining HA; Bakker WH; Krenning EP
J Clin Endocrinol Metab; 1990 Sep; 71(3):566-74. PubMed ID: 2168430
[TBL] [Abstract][Full Text] [Related]
6. Receptor scintigraphy with 111In-pentetreotide for endocrine gastroenteropancreatic tumors.
Joseph K; Stapp J; Reinecke J; Skamel HJ; Höffken H; Neuhaus C; Lenze H; Trautmann ME; Arnold R
Horm Metab Res Suppl; 1993; 27():28-35. PubMed ID: 8330869
[TBL] [Abstract][Full Text] [Related]
7. [Somatostatin receptor scintigraphy in preoperative diagnosis of the site of endocrine gastrointestinal tumors].
Weinel RJ; Kisker O; Joseph K; Welcke U; Zaraca F; Rothmund M
Chirurg; 1994 Oct; 65(10):849-55. PubMed ID: 7821043
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin-receptor imaging in the localization of endocrine tumors.
Lamberts SW; Bakker WH; Reubi JC; Krenning EP
N Engl J Med; 1990 Nov; 323(18):1246-9. PubMed ID: 2170840
[TBL] [Abstract][Full Text] [Related]
9. Management of gastroenteropancreatic endocrine tumors: the place of somatostatin analogues.
Arnold R; Frank M; Kajdan U
Digestion; 1994; 55 Suppl 3():107-13. PubMed ID: 7698532
[TBL] [Abstract][Full Text] [Related]
10. The value of somatostatin-receptor scintigraphy in newly diagnosed endocrine gastroenteropancreatic tumors.
Kisker O; Bartsch D; Weinel RJ; Joseph K; Welcke UH; Zaraca F; Rothmund M
J Am Coll Surg; 1997 May; 184(5):487-92. PubMed ID: 9145069
[TBL] [Abstract][Full Text] [Related]
11. Use of an isotopic somatostatin receptor probe to image gut endocrine tumors.
Modlin IM; Cornelius E; Lawton GP
Arch Surg; 1995 Apr; 130(4):367-73; discussion 373-4. PubMed ID: 7710334
[TBL] [Abstract][Full Text] [Related]
12. Treatment with Sandostatin and in vivo localization of tumors with radiolabeled somatostatin analogs.
Lamberts SW; Bakker WH; Reubi JC; Krenning EP
Metabolism; 1990 Sep; 39(9 Suppl 2):152-5. PubMed ID: 2169572
[TBL] [Abstract][Full Text] [Related]
13. [Phase 3 multicenter clinical study of 111In-DTPA-D-octreotide (MP-1727) in patients with gastrointestinal hormone producing tumors].
Yamamoto K; Ishii Y; Furudate M; Ito K; Tsukamoto E; Kanamaru R; Endo K; Hirano T; Tanaka K; Ogino Y
Kaku Igaku; 1995 Nov; 32(11):1269-80. PubMed ID: 8558797
[TBL] [Abstract][Full Text] [Related]
14. [Therapy of endocrine gastrointestinal-pancreatic tumors with somatostatin analog octreotide].
Arnold R; Neuhaus C; Trautmann ME
Dtsch Med Wochenschr; 1992 Jul; 117(27):1067-71. PubMed ID: 1352235
[No Abstract] [Full Text] [Related]
15. [111In-pentetreotide in the study of tumors expressing somatostatin receptors].
Mateos Fernández J; Pons Pons F; Fuster Pelfort D; Vidal-Sicart S; Lomeña Caballero F; Herranz García-Romero R
Rev Esp Med Nucl; 1999 Oct; 18(5):325-30. PubMed ID: 10562660
[TBL] [Abstract][Full Text] [Related]
16. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours.
Angeletti S; Corleto VD; Schillaci O; Moretti A; Panzuto F; Annibale B; Delle Fave G
Ital J Gastroenterol Hepatol; 1999; 31(1):23-7. PubMed ID: 10091100
[TBL] [Abstract][Full Text] [Related]
17. [Primary and follow-up studies of patients with carcinoid metastases using indium 111 octreotide--rational use of Sandostatin].
Lipp RW; Hammer HF; Passath A; Dobnig H; Ramschak-Schwarzer S; Stiegler C; Leb G; Krejs GJ
Acta Med Austriaca; 1993; 20(1-2):42-4. PubMed ID: 8475679
[TBL] [Abstract][Full Text] [Related]
18. L-3-[123I]Iodo-alpha-methyltyrosine scintigraphy in carcinoid tumors: correlation with biochemical activity and comparison with [111In-DTPA-D-Phe1]-octreotide imaging.
Jager PL; Meijer WG; Kema IP; Willemse PH; Piers DA; de Vries EG
J Nucl Med; 2000 Nov; 41(11):1793-800. PubMed ID: 11079485
[TBL] [Abstract][Full Text] [Related]
19. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma.
Shojamanesh H; Gibril F; Louie A; Ojeaburu JV; Bashir S; Abou-Saif A; Jensen RT
Cancer; 2002 Jan; 94(2):331-43. PubMed ID: 11900219
[TBL] [Abstract][Full Text] [Related]
20. [Use of octreotide in the treatment of digestive endocrine tumors. A French multicenter study].
Blanchin M; James-Deidier A; Chaumet-Riffaud PD; Chayvialle JA
Presse Med; 1992 Apr; 21(15):697-702. PubMed ID: 1376476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]